Studies METTL-14 protein levels in womb lining cancer tissue samples
Looks at METTL14 levels in tumor samples from people with endometrial cancer.
Plain-language title generated from the registry record
Registry title: Prognosis of METTL-14 in Endometrial Carcinoma
Key facts
- Where
- Asyut, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with type 1 endometrial cancer who had a hysterectomy and have full medical records and three years of follow-up data.
- Sex
- Women only.
- Disease stage
- Type 1 endometrial carcinoma.
- Earlier treatment
- Must have had a hysterectomy (surgery to remove the womb).
- Biomarker or test result
- Tumor tissue is tested for METTL14. Stained slides or a paraffin-embedded tissue block must be available.
Main reasons for not taking part
- Missing clinical, radiology or follow-up data
- No stained slides or paraffin-embedded tissue block available
- Cases with D&C only
Read by machine on 9 November 2026.
Where in Egypt
- AssuitUAsyut, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assiut University
- Trial code
- NCT06861855
- Record updated
- 30 September 2025
- Original description
1. To evaluate immunohistochemical expression of METTL14 in type1 endometrial carcinoma. 2. To evaluate the correlation between METTL14 expression and clinicopathological parameters of patients with type 1endometrial carcinoma such as tumor grade, lymhovascular invasion, age of pateints, tumor stage, presence of myometrial invasion and presence of cervical stroma affection. 3. To assess correlation of METTL-14 expression with disease free survival and overall survival.Read full original descriptionShow less
Prognostic Impact of Immunohistochemical Expression of METTL-14 in Endometrial Carcinoma
1. To evaluate immunohistochemical expression of METTL14 in type1 endometrial carcinoma. 2. To evaluate the correlation between METTL14 expression and clinicopathological parameters of patients with type 1endometrial carcinoma such as tumor grade, lymhovascular invasion, age of pateints, tumor stage, presence of myometrial invasion and presence of cervical stroma affection. 3. To assess correlation of METTL-14 expression with disease free survival and overall survival.
Inclusion: Cases of type1endometrial carcinoma with:; Hystrectomy operation; Available full clinical data about patient (age, complaint, findings in clinical examination); Full data about previous biopsy and radiology; Full data about patient survival, disease progression and history of chemotherapy for three years.
Exclusion: 1. Any case of type 1 endometrial carcinoma with missing clinical, radiologic or follow up data; Cases with no available H\&E stained slides or formalin fixed paraffin embedded block; 3.D\&C.